In the presented study we tested the effect of the bi-and monocyclic analogues of mitoguazone on neoplastic activity of methotrexate in the model of L1210 leukemia in mice. We have demonstrated that combined therapy involving administration of methotrexate with 2-oxo-propanal bis (4,5,6,7 -tetrahydro-IH-l,3-diazepin-2-yl)methylhydrazone dihydroiodide (aM 7) at different doses is more effective than methotrexate monotherapy in mice inoculated with L1210 leukemia.
Introduction
Methotrexate, a folate antagonist, is an antineoplastic drug which possesses a well-established position in chemotherapy. The mechanism of its activity involves blocking dihydrotolate reductase, as well as another enzyme crucial tor DNA synthesis-timidilane synthase. The latter enzyme is blocked by methotrexate polyglutamates. The drug is most frequently used in combined therapy (1) .
Mitoguazone is a representative of the next generation of antitumor agents. It was introduced to the oncologicol practice in 1974 (2) .
Mitoguazone is an inhibitor of S-adenosylmethionine decarboxylase (SAM DC) an enzyme which takes part in the synthesis of polyamines. Polyamine metabolic cycle inhibitors constitute a promising molecular target in the search for new chemotherapeutic agents. Mitoguazone is used in combined therapy. § Author to whom correspondence should be addressed.
Favourable effects of the combinations of this drug with methotrexate, ifosfamide and etoposide have been obtained (3) . However, because of its low therapeutic index, as well as adverse effects, mitoguazone analogues have been investigated in order to find the compounds which also block the synthesis of polyamines but have better therapeutic indices. Among the new analogues the most promising one seems to be amidine indanone amidinohydrazone, synthesised by Ciba Geigy, which is now undergoing clinical trials (4) .
The aim of the present study was to investigate the effects of newly -synthesised bicyclic and monocyclic methylglyoxal derivatives (5) on neoplastic actiyit:y of MTX in the in vivo model of L1210 lymphoid leukemia in mice.
Materials and Methods

Animals
The experiments were performed on mICe of 
Leukemia
Lymphoid leukemia L1210 cells were obtained from the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (Wrodaw), and were maintained by serial passage in the ascitic fluid of DBA/2 mice. Leukemic cells L1210 from the fluid were resuspended in 0.9% sodium chloride and 3 x 105 cells/mouse were injected i.p. into BDFI recipients.
Therapeutics
Methotrexate (Lederle) was dissolved tn 0.9%
:-'te ridines/ Vol. 9 / No. 4 sodium chloride. Mitoguazone analogues, marked with the symbols: aM 5, aM 7 , aM 8 and aM 9 were suspended in 1 % aqueous solution of methylcelulose. The study was carried out in vivo, assessing the survival period of mice inoculated with L1210 leukemia.
Methotrexate and mitoguazone analogues were administered 24 h after inoculation with L1210 leukemia as single doses injected intraperitoneally, according to the following schedules:
-methotrexate in monotherapy -methotrexate and mitoguazone analogue marked with aM 5 symbol -methotrexate and mitoguazone analogue marked with aM 7 symbol -methotrexate and mitoguazone analogue marked with aM 8 symbol -methotrexate and mitoguazone analogue marked with aM 9 symbol.
Methotrexate and mitoguazone analogues were administered in various combinations of methotrexate or analogue doses: 0 .5 LD so , 0 .25 LD so , 0 . MTX and investigated compounds were administered as separate intraperitoneal injections. The first injection was always MTX. The time interval between the administration of MTX and a mitoguazone analogue (aM) was not longer than 5 min. MTX and aM's were prepared at various concentrations so that each dose was administered in the volume of 0.1 mljlO g b.w. The mice constituting the control, untreated group, received 0.1 ml/ lOg b .w . of 1% methylcelulose solution. The planned observation time was 30 days or till the day of the animal's death.
The survival time in groups receiving combined therapy was compared with the survival time of mice in the untreated control group and in the group of mice treated with MTX monotherapy.
Prior to investigation of the effects of the above compounds on mice inoculated with LI210 leukemia, the planned treatment schedules were tested on health animals to determine their general cytotoxicity.
Statistical analysis
The difterences of parameters values among the gro ups \\·ere calculated using Student -t test with the IC\·el of significance set at p:::;; 0.05 . Table 1 presents the effects of single administration of MTX combined with aM's at different doses constituting fractions of LDso values on survival times of healthy mice . The animals were observed for 30 days after the administration of drugs.
Results
The schedules: 0 .5 LDso of MTX with 0 .5 LDso aM 5 or aM 9, as well as 0.25 LDso MTX with Table 1 Thus, antineoplastic effects in mice with L1210 leukemia were tested using MTX with each of mitoguazone analogues in the combination of doses that not lethal for healthy mice. Table 2 presents the survival of mice inoculated with L1210 leukemia, treated with MTX monotherapy and combined therapy using MTX and aM's .
A significant increase of survival time was demonstrated in mice with L1210 leukemia treated with MTX administered as monotherapy as well as in combined therapy with aM 5, aM 7, aM 8 or aM 9 in comparison with untreated leukemic mice . The values of T IC (=treatedl control) were higher than 125%. [An investigated substance is regarded as possessing antitumo r properties at a particular dose (doses administered to an animal, if the survival time of the treated group in comparison with the control group is prolonged by at least 25%) (6) . Thus, the T /C% index value must be ;;::: 125%].
No statistically significant differences were found between survival times of animals treated with MTX combined with mitoguazone analogues aM 5 , aM 8, aM 9 for most of the used schedules as compared with mice treate d with MTX monotherapy. However, it was demonstrated that combined therapy consisting of MTX at 0.5 LDso dose and mitoguazone analogue aM 7 at 0. 
Discussion
Combined therapy is essential approach in the treatment of neoplastic diseases. It allows to utilise favourable pharmacokinetic and/or pharmacodynamic. It is also possible to avoid high doses o f one drug, as in monotherapy, and effects of combined therapy with these compounds and MTX, anticipating the possibility of interaction on various metabolic pathways of neoplastic proliferating cells. We have demonstrated that combined therapy involving administration of MTX with aM 7 at different doses is more effective than methotrexate monotherapy in mice innoculated with LI2IO leukemia.
More comprehensive studies concerning combined therapy with MTX and this mitoguazone analogue according to different schedules are planned.
